anti cancer medicine

Sunitcap 25mg Capsule: Advanced Multi-Targeted Tyrosine Kinase Inhibition for Global Oncology Sourcing Are you searching for a verified Sunitcap 25mg Capsule exporter from India? Ernest Oncology, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We facilitate a secure, high-standard supply chain for London & the UK, the USA, Australia, and South Africa, ensuring that critical tyrosine kinase inhibitors (TKIs) reach healthcare providers with 100% pharmaceutical integrity. Detailed Product Profile: What is Sunitcap 25mg? Sunitcap 25mg is an oral, multi-targeted Tyrosine Kinase Inhibitor (TKI) containing the active pharmaceutical ingredient Sunitinib Malate. Manufactured by Allieva, this 25mg strength is a specialized formulation designed to target the specific proteins that cancer cells use to grow, divide, and develop the blood vessels they need to survive. 1. Therapeutic Indications Advanced Renal Cell Carcinoma (RCC): A first-line therapy for advanced or metastatic kidney cancer. Gastrointestinal Stromal Tumors (GIST): Specifically for patients whose disease has progressed on or who are intolerant to imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Used for progressive, well-differentiated tumors in patients with unresectable, locally advanced, or metastatic disease. Adjuvant Treatment: In certain high-risk settings, it is used to reduce the risk of cancer returning after nephrectomy (kidney surgery). 2. Mechanism of Action: The Dual-Action Blockade Anti-Angiogenesis: It blocks the Vascular Endothelial Growth Factor Receptors (VEGFR) and Platelet-Derived Growth Factor Receptors (PDGFR). This effectively “starves“ the tumor by preventing it from forming the new blood vessels required for nutrient delivery. Direct Anti-Tumor Activity: It inhibits KIT (CD117), RET, and FLT3, which are signaling proteins that drive the uncontrolled multiplication of cancer cells. This combined inhibition stops the signaling pathways, leading to tumor shrinkage and delayed disease progression. 3. Administration and Usage Dosing Schedule: Often taken in a “4 weeks on, 2 weeks off“ cycle, or as a continuous daily dose depending on the specific clinical indication. Timing: Can be taken with or without food. Consistency in daily timing is key for maintaining therapeutic blood levels. Precautions: Patients should avoid grapefruit and grapefruit juice, as they can significantly increase the drug's concentration in the blood, leading to toxicity. Clinical Side Effects & Safety Monitoring Fatigue & Asthenia: High levels of tiredness are a common clinical observation. Gastrointestinal Distress: Diarrhea, nausea, vomiting, stomatitis (mouth sores), and altered taste (dysgeusia). Dermatological Reactions: Hand-Foot Syndrome (redness, pain, or swelling on palms and soles), skin yellowing (not jaundice), or changes in hair color. Hypertension: High blood pressure is a frequent side effect and must be managed medically. Hematological: Decreased blood counts (neutropenia, thrombocytopenia); regular blood tests are mandatory. Endocrine: Hypothyroidism (underactive thyroid) is a known side effect requiring periodic thyroid function tests. Why Source Sunitcap 25mg from Ernest Oncology? Verified Authenticity: Direct sourcing of Allieva’s Sunitcap with full batch-specific traceability and COA. Logistics Authority: Expert handling of import regulations for London (UK), the USA, Australia, and South Africa. Wholesale Fulfillment: Competitive bulk pricing and steady inventory for hospital groups, specialty clinics, and regional distributors. Regulatory Compliance: Every shipment is accompanied by GMP certificates and complete B2B documentation. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: Chat on WhatsApp

SUNITCAP 12.5 MG Capsule (Sunitinib): Multi-Targeted Tyrosine Kinase Inhibition for Advanced Oncology SUNITCAP 12.5 MG Capsule is a sophisticated oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. As a powerful multi-targeted receptor tyrosine kinase (RTK) inhibitor, it is designed to disrupt the signaling pathways that tumors use to grow, divide, and develop a blood supply. Manufactured under stringent GMP quality standards, SUNITCAP 12.5 MG is a critical therapeutic intervention utilized globally to manage specific solid tumors that have become resistant to standard therapies. Therapeutic Indications and Global Clinical Usage Gastrointestinal Stromal Tumor (GIST): Indicated for the treatment of GIST after disease progression on or intolerance to imatinib mesylate. Advanced Renal Cell Carcinoma (RCC): Used as a primary or secondary treatment for advanced or metastatic kidney cancer. Pancreatic Neuroendocrine Tumors (pNET): Indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Mechanism of Action: How SUNITCAP 12.5 MG Works Inhibition of Angiogenesis: It blocks the Vascular Endothelial Growth Factor Receptors (VEGFR), which tumors use to grow new blood vessels to feed themselves. Proliferation Blockade: It targets Platelet-Derived Growth Factor Receptors (PDGFR) and other kinases (like KIT and FLT3), shutting down the “growth signals“ that tell cancer cells to multiply. Dual Action: By simultaneously starving the tumor of its blood supply and stopping cell division, SUNITCAP effectively induces tumor shrinkage and prevents further metastasis. Common Side Effects: Gastrointestinal: Diarrhea, nausea, vomiting, and altered taste (dysgeusia). Dermatological: Skin discoloration (yellowish tint), dry skin, and hand-foot syndrome (redness or swelling of palms/soles). Systemic: Fatigue, high blood pressure (hypertension), and mucosal inflammation. Hematological: Potential decrease in white blood cell or platelet counts. Professional Administration and Safety Protocols Route: Oral administration (capsule). Timing: Can be taken with or without food. Clinical Monitoring: Regular monitoring of blood pressure, heart function (LVEF), and thyroid function is mandatory during treatment. Precise Titration: The 12.5 mg strength is often used in a “4 weeks on, 2 weeks off“ schedule or continuous dosing, depending on the specific cancer type. Storage and Global Handling Instructions Storage: Store at controlled room temperature (20°C to 25°C). Packaging: Keep capsules in the original bottle to protect them from moisture and light. Why Choose Ernest Oncology? 100% Genuine Medication: Sourced directly from GMP-certified channels for maximum efficacy. Verified Global Export Network: We facilitate rapid and secure shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Logistics Precision: Our team manages pharmaceutical exports with expertise, utilizing secure packaging to maintain product stability during transit. Regulatory Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA), for seamless customs clearance. Bulk Supplier Advantage: Competitive wholesale rates to support oncology hospitals, specialized pharmacies, and government health departments. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestimpex.com www.ernestvision.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 https://wa.me/919359902383

HYCALIEVA 2.5 MG Injection (Topotecan): Targeted Topoisomerase I Inhibition for Relapsed Malignancies HYCALIEVA 2.5 MG Injection is a sophisticated antineoplastic agent featuring the active pharmaceutical ingredient Topotecan Hydrochloride. As a semi-synthetic derivative of camptothecin, it serves as a potent inhibitor of the enzyme topoisomerase I. Manufactured under stringent GMP quality standards, HYCALIEVA 2.5 MG is a critical therapeutic intervention utilized globally to manage advanced-stage solid tumors that have shown resistance to primary treatments. Therapeutic Indications and Global Clinical Usage Small Cell Lung Cancer (SCLC): Indicated for the treatment of patients with relapsed SCLC for whom first-line chemotherapy is no longer effective. Advanced Ovarian Cancer: Used as a single-agent therapy for patients with metastatic ovarian carcinoma after the failure of initial or subsequent chemotherapy. Cervical Cancer: Frequently used in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent carcinoma of the cervix. Pediatric Oncology: Occasionally utilized in specialized research-based protocols for neuroblastoma and other pediatric solid tumors. Mechanism of Action: How HYCALIEVA 2.5 MG Works Enzyme Binding: The drug binds to the topoisomerase I-DNA complex. This enzyme is normally responsible for relieving the torsional strain in DNA by creating reversible single-strand breaks. Complex Stabilization: HYCALIEVA stabilizes these single-strand breaks, preventing the DNA from “re-ligating“ or joining back together. DNA Fragmentation: When the cell attempts to replicate its DNA, the replication fork collides with the stabilized drug-enzyme complex, leading to lethal double-strand DNA breaks. Cellular Apoptosis: The cancer cell is unable to repair this extensive genetic damage, triggering programmed cell death (apoptosis) and halting tumor growth. Common Side Effects: Hematological: Significant bone marrow suppression, including neutropenia (low white blood cells), anemia, and thrombocytopenia. Gastrointestinal: Nausea, vomiting, diarrhea, and stomatitis (mouth sores). General: Fatigue, fever, and generalized weakness (asthenia). Dermatological: Mild hair loss (alopecia) and skin rashes. Professional Administration and Safety Protocols Route: Administered strictly via Intravenous (IV) Infusion. Infusion Schedule: Typically administered daily for 5 consecutive days in a 21-day cycle, though schedules vary by indication. Reconstitution: Must be reconstituted with sterile water for injection and further diluted with 0.9% sodium chloride or 5% Dextrose. Clinical Oversight: Must be administered by specialized oncology teams in settings equipped for real-time monitoring of hematological status. Storage and Global Handling Instructions Storage: Store the un-reconstituted vial at controlled room temperature (20°C to 25°C) and protect from light. Handling: As a hazardous cytotoxic agent, HYCALIEVA 2.5 MG must be handled using appropriate Personal Protective Equipment (PPE) and disposed of according to international biohazard protocols. Why Choose Ernest Oncology? 100% Genuine Medication: Sourced directly from GMP certified channels for maximum safety. Global Distribution Network: Secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Logistics Precision: Our team manages pharmaceutical exports with expertise, utilizing secure packaging to maintain product stability. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA), for seamless customs clearance. Bulk Supplier Advantage: Competitive wholesale rates to support oncology hospitals, clinics, and government health programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestimpex.com www.ernestvision.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 https://wa.me/919359902383

DACTOLIEVA 0.5 MG Injection (Dactinomycin): High-Potency Cytotoxic Antibiotic for Rare and Pediatric Malignancies DACTOLIEVA 0.5 MG Injection is a highly specialized antineoplastic medication featuring the active pharmaceutical ingredient Dactinomycin (also known as Actinomycin D). Derived from Streptomyces parvullus, this cytotoxic antibiotic is a cornerstone in the treatment of specific rare cancers and pediatric malignancies. Manufactured under stringent GMP quality standards, DACTOLIEVA 0.5 mg is engineered to deliver precise therapeutic intervention for complex oncology cases across the USA, UK, Europe, UAE, and Asia. Therapeutic Indications and Global Clinical Usage Wilms’ Tumor: A primary agent in the management of this pediatric kidney cancer, often used in combination with vincristine. Rhabdomyosarcoma: Utilized in combination regimens for this aggressive soft tissue sarcoma, particularly in children. Ewing's Sarcoma: Integrated into multi-drug protocols for bone and soft tissue tumors. Trophoblastic Neoplasia: Used in the treatment of gestational choriocarcinoma, especially in patients resistant to other therapies. Testicular Cancer: Part of combination cycles for non-seminomatous germ cell tumors. Mechanism of Action: How DACTOLIEVA 0.5 MG Works Intercalation: The Dactinomycin molecule slides between the base pairs (specifically guanine-cytosine) of the DNA double helix. Transcription Blockade: By binding to the DNA, it physically blocks the movement of RNA polymerase, the enzyme responsible for reading DNA. RNA Synthesis Inhibition: This stops the production of messenger RNA (mRNA), which is essential for the cell to create proteins. Cytotoxic Effect: Without the ability to synthesize proteins or replicate its genetic material correctly, the malignant cell ceases to grow and eventually undergoes apoptosis. Common Side Effects Hematological: Anemia, leukopenia (low white blood cells), and thrombocytopenia (low platelets). Gastrointestinal: Nausea, vomiting, loss of appetite, and mouth sores (mucositis). Dermatological: Skin rash, hair loss (alopecia), and “radiation recall“ (skin reactions at previous radiation sites). General: Fatigue, malaise, and potential liver enzyme elevations. Professional Administration and Safety Protocols Route: Administered strictly via intravenous (IV) injection or infusion. Extravasation Risk: This drug is a potent vesicant. Extreme care must be taken to ensure it does not leak into the surrounding tissue, as this can cause severe tissue damage. Precision Dosing: Dosages are frequently calculated based on body surface area ($mg/m^2$) or body weight ($mcg/kg$). Clinical Oversight: Must be administered by specialized oncology teams in settings equipped for the management of cytotoxic toxicities. Storage and Global Handling Instructions Storage: Store the unreconstituted vial at controlled room temperature (20°C to 25°C) and protect from light. Handling: As a hazardous cytotoxic agent, DACTOLIEVA 0.5 MG must be handled using specialized personal protective equipment (PPE) and disposed of according to international biohazard protocols. Why Choose Ernest Oncology? 100% Genuine Medication: Sourced directly from GMP-certified channels for maximum safety. Global Distribution Network: Secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Logistics Precision: Our team manages pharmaceutical exports with expertise, utilizing secure packaging to maintain product stability. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA), for seamless customs clearance. Bulk Supplier Advantage: Competitive wholesale rates to support oncology hospitals, pediatric centers, and government health programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestimpex.com www.ernestvision.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 https://wa.me/919359902383

TREXLIEVA 500 MG Injection (Methotrexate): High-Strength Antimetabolite for Intensive Oncology Care TREXLIEVA 500 MG Injection is a high-concentration antineoplastic medication featuring the active pharmaceutical ingredient Methotrexate. As a potent folate antagonist, it is a critical component of high-dose chemotherapy regimens used to treat aggressive malignancies. Manufactured under rigorous GMP quality standards, TREXLIEVA 500 MG is engineered to deliver the intensive therapeutic intervention required for systemic cancer management across the USA, UK, Europe, UAE, and Asia. Therapeutic Indications and Global Clinical Usage Acute Lymphocytic Leukemia (ALL): Often used in intensification and maintenance phases to eliminate residual cancer cells. Osteosarcoma: A primary agent in high-dose regimens for malignant bone tumors, typically followed by leucovorin calcium rescue. Non-Hodgkin’s Lymphoma: Employed for systemic treatment and the prevention of central nervous system (CNS) involvement. Gestational Trophoblastic Neoplasia: Used in the treatment of choriocarcinoma and related trophoblastic diseases. Advanced Breast Cancer: Integrated into combination cycles for patients with metastatic disease Mechanism of Action: How TREXLIEVA 500 MG Works Enzyme Targeting: TREXLIEVA inhibits the enzyme dihydrofolate reductase (DHFR) with extreme precision. Folate Depletion: By blocking DHFR, the drug prevents the conversion of folic acid into its active form, tetrahydrofolate. DNA Synthesis Arrest: Tetrahydrofolate is a critical co-factor needed to create thymidylate and purines—the building blocks of DNA and RNA. S-Phase Specificity: The drug primarily affects cells in the S-phase of the cell cycle (when they are actively making new DNA), making it highly effective against rapidly dividing malignant cells. Cytotoxic Outcome: Without the ability to synthesize DNA, the cancer cell cannot divide and eventually undergoes programmed cell death. Professional Administration and Safety Protocols Route: Administered via Intravenous (IV) Infusion, Intramuscular (IM), or Intrathecal injection (in specific settings). High-Dose “Rescue“ Protocol: When using the 500 MG strength, administration of Leucovorin Calcium (Folinic Acid) is mandatory at specific intervals to protect healthy cells from lethal folate deficiency. Alkaline Diuresis: Patients receiving high doses must be aggressively hydrated and administered sodium bicarbonate to keep urine pH alkaline, preventing the drug from precipitating in the kidneys. Clinical Oversight: Must be administered by specialized oncology teams in settings equipped for real-time monitoring of serum methotrexate levels. Safety Profile and Clinical Monitoring Hematological Vigilance: Frequent Complete Blood Counts (CBC) are required to monitor for significant bone marrow suppression (neutropenia and thrombocytopenia). Nephrotoxicity Monitoring: Constant checks of serum creatinine and urine output are essential to prevent renal failure. Hepatotoxicity: Periodic liver function tests (LFTs) to monitor for treatment-induced hepatic strain. Mucositis Monitoring: Vigilance for severe inflammation of the mucous membranes, a common side effect of high-dose folate inhibition. Storage and Global Handling Instructions Storage: Store at controlled room temperature (20°C to 25°C) and protect the vial from light. Handling: As a hazardous cytotoxic agent, TREXLIEVA 500 MG must be prepared using specialized Personal Protective Equipment (PPE) and disposed of according to international biohazard protocols. Why Source TREXLIEVA 500 MG from Ernest Oncology? 100% Genuine Medication: Sourced directly from GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Global Distribution Network: Secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Logistics Precision: Our team manages pharmaceutical exports with expertise, utilizing secure packaging and efficient transit routes to maintain product stability. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, research clinics, and government health departments. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestimpex.com www.ernestvision.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 https://wa.me/919359902383

IRILIEVA 100 MG Injection (Irinotecan): Advanced Topoisomerase I Inhibitor for Colorectal and Gastrointestinal Malignancies IRILIEVA 100 MG Injection is a potent antineoplastic agent featuring the active pharmaceutical ingredient Irinotecan Hydrochloride. As a derivative of camptothecin, it serves as a semi-synthetic inhibitor of the enzyme topoisomerase I. Manufactured under rigorous GMP quality standards, IRILIEVA 100 MG is a critical therapeutic intervention utilized globally to manage advanced-stage solid tumors, particularly those affecting the gastrointestinal tract. Therapeutic Indications and Global Clinical Usage Metastatic Colorectal Cancer (mCRC): Indicated as a first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (the FOLFIRI regimen) or as a single agent for patients whose disease has recurred or progressed following initial fluorouracil-based therapy. Pancreatic Adenocarcinoma: Frequently utilized in combination with other agents (such as in the FOLFIRINOX regimen) for the treatment of metastatic pancreatic cancer. Small Cell Lung Cancer (SCLC): Often employed in specialized treatment lines for patients with extensive-stage lung cancer. Gastroesophageal Malignancies: Used in various systemic protocols for advanced stomach or esophageal cancers. Mechanism of Action: How IRILIEVA 100 MG Works Enzyme Inhibition: The drug binds to the topoisomerase I-DNA complex. This enzyme is responsible for relieving torsional strain in DNA by inducing single-strand breaks. Stabilization of Cleavable Complexes: IRILIEVA prevents the “re-ligation“ (re-joining) of these single-strand breaks. DNA Damage: When the replication fork collides with these stabilized complexes, double-strand DNA breaks are formed. Cellular Apoptosis: Malignant cells are unable to repair these lethal double-strand breaks, leading to irreversible DNA damage and programmed cell death (apoptosis). Professional Administration and Safety Protocols Route: Administered strictly via Intravenous (IV) Infusion. Dilution: Must be diluted in 5% Dextrose Injection (D5W) or 0.9% Sodium Chloride Injection (Normal Saline) before administration. Infusion Time: Standard protocols typically require an infusion duration of 30 to 90 minutes. Clinical Oversight: Must be administered by trained oncology professionals in a setting equipped for the management of acute cholinergic symptoms and delayed diarrhea. Safety Profile and Clinical Monitoring Gastrointestinal Vigilance: Monitoring for “Early Diarrhea“ (cholinergic syndrome) occurring during or shortly after infusion, and “Delayed Diarrhea“ occurring more than 24 hours post-administration. Immediate intervention with loperamide is standard protocol for delayed symptoms. Hematological Monitoring: Regular Complete Blood Counts (CBC) are mandatory to monitor for severe neutropenia and anemia. Hepatic Function: Periodic liver function tests (LFTs) are required, as the drug is primarily metabolized and excreted via the liver and biliary tract. Cholinergic Symptoms: Vigilance for symptoms like sweating, abdominal cramping, and increased salivation, which may require atropine intervention. Storage and Global Handling Instructions Storage: Store at controlled room temperature (20°C to 25°C) and protect from light. Handling: As a hazardous cytotoxic antineoplastic agent, IRILIEVA 100 MG must be prepared and handled using appropriate Personal Protective Equipment (PPE) and disposed of according to international biohazard protocols. Why Choose Ernest Oncology? 100% Genuine Medication: Sourced directly from GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Global Distribution Network: Secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Logistics Precision: Our team manages pharmaceutical exports with expertise, utilizing secure packaging and efficient transit routes to maintain product stability. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, clinics, and government health programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestimpex.com www.ernestvision.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 https://wa.me/919359902383

ZODLIEVA 4 mg Injection (Zoledronic Acid): The Gold Standard in Bone Health and Supportive Oncology ZODLIEVA 4 mg Injection is a high-potency bisphosphonate containing the active pharmaceutical ingredient Zoledronic Acid (often referred to as Zoledronate). It is a critical supportive care medication used globally to manage and prevent skeletal-related events in patients with advanced malignancies. By targeting bone metabolism, ZODLIEVA 4mg helps preserve skeletal integrity, reduce bone pain, and manage life-threatening electrolyte imbalances. Therapeutic Indications and Clinical Applications Bone Metastases from Solid Tumors: Indicated for patients with advanced cancers (such as breast, prostate, or lung cancer) that have spread to the bone, helping to prevent fractures and spinal cord compression. Multiple Myeloma: Used to treat bone lesions and prevent skeletal complications in patients diagnosed with plasma cell dyscrasias. Hypercalcemia of Malignancy (HCM): A life-saving intervention used to rapidly reduce and stabilize dangerously high calcium levels in the blood caused by tumor activity. Osteoporosis Management: In certain clinical settings, it is used to increase bone mass and reduce the risk of fractures in high-risk patients. Mechanism of Action: How ZODLIEVA 4mg Works Cytoskeletal Disruption: This blockade disrupts the internal structure of the osteoclast, causing it to lose its ability to resorb bone. Apoptosis: The drug ultimately triggers programmed cell death (apoptosis) in overactive osteoclasts. Mineral Retention: By stopping excessive bone breakdown, ZODLIEVA prevents the release of calcium into the bloodstream and strengthens the bone matrix. Professional Administration and Dosage Route: Administered strictly via Intravenous (IV) Infusion. Infusion Duration: The 4mg dose must be administered over at least 15 minutes. Rapid infusion can significantly increase the risk of renal toxicity. Hydration: Patients must be adequately hydrated before and after administration to protect kidney function. Frequency: For bone metastases, it is typically administered once every 3 to 4 weeks, or as directed by the oncologist. Safety Profile and Clinical Oversight Renal Function: Serum creatinine levels must be checked before every dose. Dosage adjustments are required for patients with mild to moderate renal impairment. Electrolyte Levels: Monitoring of serum calcium, phosphate, and magnesium is essential to prevent hypocalcemia. Oral Health (ONJ): Patients should undergo a dental exam before starting treatment, as bisphosphonates are linked to a rare condition called Osteonecrosis of the Jaw (ONJ). Acute Phase Reaction: Some patients may experience “flu-like“ symptoms (fever, muscle pain, fatigue) within the first three days of the initial infusion. Why Choose Ernest Oncology? 100% Authentic Supply: We source ZODLIEVA directly from GMP-certified facilities, ensuring product integrity and long shelf life. Global Logistics Network: We provide rapid and secure shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, the Middle East, Africa, and Asia. Regulatory Documentation: Every shipment includes the necessary Certificates of Analysis (CoA) and export documentation for hassle-free customs clearance. Wholesale Bulk Supply: We offer competitive pricing models for oncology hospitals, clinics, and government health departments worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestimpex.com www.ernestvision.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

GEMLIEVA 1000 MG Injection (Gemcitabine): High-Capacity Nucleoside Analog for Comprehensive Oncology GEMLIEVA 1000 MG Injection is a high-dose antineoplastic medication featuring the active pharmaceutical ingredient Gemcitabine. Classified as a pyrimidine nucleoside analog (antimetabolite), it is a vital component in the systemic treatment of several aggressive solid tumors. Manufactured under strict GMP guidelines, GEMLIEVA 1000 MG is designed to deliver a high concentration of the active agent, facilitating clinical efficiency for high-volume oncology centers across the USA, UK, Europe, UAE, and Asia. Therapeutic Indications and Global Clinical Usage Advanced Pancreatic Cancer: Indicated as the standard first-line treatment for patients with locally advanced or metastatic adenocarcinoma of the pancreas. Non-Small Cell Lung Cancer (NSCLC): Used in combination with cisplatin for the treatment of patients with inoperable, locally advanced, or metastatic NSCLC. Metastatic Breast Cancer: Employed in combination with paclitaxel for patients who have relapsed following prior anthracycline-containing adjuvant chemotherapy. Advanced Ovarian Cancer: Used in combination with carboplatin for patients with relapsed disease following platinum-based first-line therapy. Bladder Cancer: Frequently utilized in combination with cisplatin for advanced or metastatic transitional cell carcinoma. Mechanism of Action: How GEMLIEVA 1000 MG Works Metabolic Activation: Once infused, Gemcitabine is converted intracellularly into active metabolites: gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). Ribonucleotide Reductase Inhibition: dFdCDP inhibits the enzyme responsible for producing the building blocks of DNA, effectively starving the cancer cell of necessary resources. Masked DNA Chain Termination: dFdCTP competes with natural building blocks for incorporation into the DNA strand. Once incorporated, only one additional nucleotide can be added, which “masks“ the drug from the cell’s repair mechanisms. Self-Potentiation: The reduction in natural building blocks (dCTP) further enhances the incorporation of the drug into DNA. Apoptosis: The irreversible structural damage to the DNA triggers programmed cell death (apoptosis), halting tumor growth. Professional Administration and Safety Protocols Route: Administered strictly via Intravenous (IV) Infusion.Infusion Duration: Typically administered over 30 minutes. Note: Extending infusion time beyond 60 minutes is associated with increased toxicity and should be avoided.Reconstitution: Usually reconstituted with 0.9% Sodium Chloride Injection to reach a final concentration suitable for infusion. Clinical Environment: This high-strength injection must be administered by trained oncology professionals in a setting equipped for continuous monitoring. Safety Profile and Clinical Monitoring Hematological Vigilance: Regular Complete Blood Counts (CBC) are mandatory to monitor for bone marrow suppression (neutropenia, thrombocytopenia, and anemia). Hepatic and Renal Function: Periodic liver function tests (LFTs) and kidney function tests (KFTs) are required, as gemcitabine can cause transient elevations in liver enzymes. Pulmonary Monitoring: Vigilance for rare but serious pulmonary toxicities, such as interstitial pneumonitis or pulmonary edema. Flu-like Symptoms: Monitoring for common side effects like fever, rash, and fatigue, which often occur within 24 hours of infusion. Storage and Global Handling Instructions Storage: Store the unreconstituted vial at controlled room temperature (20°C to 25°C). Protection: Keep the vial in the original packaging to protect from light. Cytotoxic Handling: As a hazardous antineoplastic agent, GEMLIEVA 1000 MG must be prepared and handled using appropriate Personal Protective Equipment (PPE) and disposed of according to international biohazard protocols. Why Choose Ernest Oncology? 100% Genuine Medication: We source directly from GMP-certified channels, ensuring product authenticity and optimal shelf life. Logistics Precision: Our team utilizes secure, pharmaceutical-grade packaging and efficient transit routes to maintain product stability during international transit. Regulatory & Documentation Support: We handle all necessary paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, clinics, and government health departments worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestimpex.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

BORTLIEVA 3.5 MG Injection (Bortezomib): High-Potency Proteasome Inhibitor for Advanced Hematology BORTLIEVA 3.5 MG Injection is a specialized antineoplastic medication featuring the active pharmaceutical ingredient Bortezomib. As the first-in-class proteasome inhibitor, it has redefined the standard of care for plasma cell malignancies. Manufactured under rigorous GMP quality standards, BORTLIEVA 3.5 MG is a critical therapeutic intervention utilized by hematologists and oncology centers worldwide to arrest cancer progression through targeted cellular regulation. Therapeutic Indications and Global Clinical Usage Multiple Myeloma: Indicated for the treatment of adult patients with previously untreated multiple myeloma (often in combination with dexamethasone or thalidomide) and for patients with relapsed or refractory disease. Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma who have received at least one prior therapy. AL Amyloidosis: Utilized in specialized off-label regimens to manage systemic light-chain amyloidosis. Combination Therapies: Frequently integrated into VMP (Bortezomib, Melphalan, Prednisone) or CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) protocols. Mechanism of Action: How BORTLIEVA 3.5 MG Works Proteasome Inhibition: Bortezomib specifically binds to the chymotrypsin-like site of the proteasome. Protein Accumulation: By blocking the proteasome, the drug prevents the breakdown of “misfolded“ or pro-apoptotic proteins. Signal Disruption: This accumulation disrupts multiple signaling cascades, specifically inhibiting NF-κB (Nuclear Factor kappa B), a protein that cancer cells use to survive and resist chemotherapy. Targeted Apoptosis: Because malignant plasma cells are highly dependent on proteasome function to manage their high protein production, they are far more sensitive to this disruption than healthy cells, leading to selective programmed cell death. Professional Administration and Safety Protocols Route: Administered via Intravenous (IV) or Subcutaneous (SC) injection. Subcutaneous administration is increasingly preferred globally to reduce the incidence of peripheral neuropathy. Reconstitution: Must be reconstituted strictly with 0.9% Sodium Chloride (Normal Saline). Dosing Schedule: Usually administered in 21-day or 35-day cycles, with specific rest periods to allow for hematological recovery. Clinical Oversight: Must be administered by trained oncology professionals in a setting equipped for continuous monitoring of neurological and hematological status. Safety Profile and Clinical Monitoring Peripheral Neuropathy: Vigilance for numbness, tingling, or burning sensations in the hands and feet. Hematological Vigilance: Regular Complete Blood Counts (CBC) are mandatory to monitor for thrombocytopenia (low platelets) and neutropenia. Antiviral Prophylaxis: Due to the risk of Herpes Zoster (shingles) reactivation, patients are often prescribed antiviral medication concurrently. Gastrointestinal Management: Monitoring for nausea, diarrhea, and potential dehydration. Storage and Global Handling Instructions Storage: Store the unreconstituted vial at controlled room temperature (20°C to 25°C) and protect from light. Reconstituted Solution: Once mixed, the solution should be used within 8 hours. Hazardous Handling: As a cytotoxic agent, BORTLIEVA 3.5 MG must be handled using specialized Personal Protective Equipment (PPE) and disposed of according to international biohazard protocols. Why Choose Ernest Oncology? 100% Genuine Medication: We source directly from GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Global Distribution Network: Secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Logistics Precision: Our team manages pharmaceutical exports with expertise, utilizing secure packaging and efficient transit routes to maintain product stability. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, clinics, and government health departments worldwide. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

LEUCOLIEVA 50 MG Injection: The Essential Cytoprotective and Biochemical Modulator in Oncology LEUCOLIEVA 50 MG Injection contains Leucovorin Calcium (also known as Folinic Acid), a reduced form of folic acid that plays a pivotal role in modern chemotherapy regimens. Unlike standard folic acid, Leucovorin does not require the enzyme dihydrofolate reductase for conversion, making it immediately bioavailable to the body's cells. Manufactured under stringent GMP guidelines, LEUCOLIEVA 50 MG is an indispensable therapeutic tool used by oncologists globally to either rescue healthy cells from high-dose toxicity or to “supercharge“ the efficacy of other chemotherapeutic agents. Therapeutic Indications and Global Clinical Usage Advanced Colorectal Cancer: Used in combination with 5-Fluorouracil (5-FU) to enhance the cytotoxic effect of the chemotherapy, significantly improving survival rates. High-Dose Methotrexate “Rescue“: Administered after high-dose Methotrexate therapy (used in Osteosarcoma or Lymphoma) to protect healthy cells from lethal folate deficiency and bone marrow suppression. Megaloblastic Anemia: Indicated for the treatment of nutritional anemias, pregnancy-related folate deficiency, or infancy-related megaloblastic anemia where oral therapy is not feasible. Accidental Overdose Management: Acts as a rapid-response agent for accidental overdoses of folic acid antagonists like trimethoprim or methotrexate. Mechanism of Action: How LEUCOLIEVA 50 MG Works The “Rescue“ Mechanism (with Methotrexate): Methotrexate works by blocking the enzyme dihydrofolate reductase. LEUCOLIEVA bypasses this block, providing the reduced folates necessary for DNA and RNA synthesis in healthy cells, effectively “rescuing“ them from the toxic effects of the drug. The “Potentiation“ Mechanism (with 5-Fluorouracil): In colorectal cancer treatment, LEUCOLIEVA binds with 5-FU and the enzyme thymidylate synthase to form a stable complex. This “triple-bind“ locks the enzyme in an inactive state longer than 5-FU could alone, leading to greater DNA disruption within the cancer cells. Professional Administration and Safety Protocols Route: Administered via Intravenous (IV) or Intramuscular (IM) injection. Incompatibility Warning: LEUCOLIEVA must NEVER be administered intrathecally (into the spinal canal), as it can be fatal. It is strictly for systemic use. Calcium Concentration: Because it contains calcium, the rate of IV injection should generally not exceed 160 mg per minute to avoid symptoms of hypercalcemia. Clinical Oversight: Must be administered by qualified oncology professionals who can precisely time the “rescue“ doses relative to the primary chemotherapy. Safety Profile and Clinical Monitoring Renal Function Monitoring: Since high-dose methotrexate and its metabolites can precipitate in the kidneys, monitoring serum creatinine and ensuring adequate hydration is mandatory. Serum Level Testing: For Methotrexate rescue, periodic blood tests to measure Methotrexate levels are required to adjust the LEUCOLIEVA dosage accurately. Hypersensitivity: Monitoring for rare allergic reactions, including urticaria or anaphylaxis. Storage and Global Handling Instructions Temperature: Store the un-reconstituted vial at controlled room temperature (20°C to 25°C) and protect from light. Reconstituted Stability: Once reconstituted, the solution should be used immediately or within the stability window specified by the manufacturer to ensure potency. Why Choose Ernest Oncology? 100% Genuine Medication: We source directly from GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Global Export Footprint: We facilitate secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Logistics Precision: Our team manages pharmaceutical exports with expertise, utilizing secure packaging and efficient transit routes to maintain product stability during long-distance transit. Regulatory & Documentation Support: We handle all necessary paperwork, including Certificates of Analysis (CoA) and export permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, pharmacy networks, and government health departments worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

BORTLIEVA 2 MG Injection (Bortezomib): Precision Proteasome Inhibition for Advanced Hematology BORTLIEVA 2 MG Injection is a specialized antineoplastic agent featuring the active pharmaceutical ingredient Bortezomib. As the first-in-class proteasome inhibitor, it has revolutionized the treatment landscape for plasma cell malignancies and certain types of lymphoma. Manufactured under stringent WHO-GMP quality standards, BORTLIEVA 2 MG is a critical therapeutic intervention utilized by hematologists and oncologists worldwide to arrest cancer progression through targeted cellular regulation. Therapeutic Indications and Global Clinical Usage Multiple Myeloma: Indicated for the treatment of adult patients with previously untreated multiple myeloma (often in combination with other agents) and for patients with relapsed or refractory disease. Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma who have received at least one prior therapy. AL Amyloidosis: Increasingly utilized in specialized regimens for systemic light-chain amyloidosis. Combination Protocols: Frequently used alongside dexamethasone, cyclophosphamide, or lenalidomide to enhance clinical outcomes. Mechanism of Action: How BORTLIEVA 2 MG Works Proteasome Binding: Bortezomib specifically binds to the chymotrypsin-like site of the 26S proteasome. Protein Accumulation: By blocking the proteasome, the drug prevents the breakdown of “misfolded“ or pro-apoptotic proteins within the cell. Signal Disruption: This accumulation disrupts multiple signaling cascades, specifically inhibiting NF-κB (Nuclear Factor kappa B), which cancer cells use to survive and resist chemotherapy. Cell Cycle Arrest: The imbalance of proteins leads to the arrest of the cell cycle and prevents the tumor from spreading (metastasis). Targeted Apoptosis: Because malignant plasma cells are highly dependent on proteasome function, they are far more sensitive to this disruption than healthy cells, leading to selective programmed cell death. Professional Administration and Safety Protocols Route: Administered via Intravenous (IV) or Subcutaneous (SC) injection. Subcutaneous administration is often preferred in modern practice to reduce the risk of peripheral neuropathy. Reconstitution: Must be reconstituted strictly with 0.9% Sodium Chloride (Normal Saline). Precise Dosing: Dosing is calculated based on Body Surface Area (BSA) and typically follows a “twice-weekly“ or “once-weekly“ schedule with rest periods to allow for recovery. Clinical Oversight: Must be administered by trained oncology professionals in a setting equipped for continuous monitoring of hematological and neurological status. Safety Profile and Clinical Monitoring Neurological Monitoring: Vigilance for treatment-induced peripheral neuropathy (numbness, tingling, or burning sensations in extremities). Hematological Vigilance: Regular Complete Blood Counts (CBC) are mandatory to monitor for thrombocytopenia (low platelets) and neutropenia. Antiviral Prophylaxis: Due to the risk of Herpes Zoster (shingles) reactivation, antiviral medication is often prescribed concurrently. Gastrointestinal Management: Monitoring for nausea, diarrhea, and dehydration, which are common but manageable side effects. Storage and Global Handling Instructions Storage: Store the un-reconstituted vial at controlled room temperature (20°C to 25°C) and protect from light. Reconstituted Stability: The reconstituted solution should be used within 8 hours. Hazardous Handling: As a cytotoxic antineoplastic agent, BORTLIEVA 2 MG must be prepared using specialized Personal Protective Equipment (PPE) and disposed of according to international biohazard protocols. Why Choose Ernest Oncology? 100% Genuine Medication: We source directly from GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Global Distribution Network: Secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Cold Chain & Logistics Precision: Our team manages pharmaceutical exports with expertise, utilizing secure packaging and efficient transit routes to maintain product stability. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, clinics, and government health departments worldwide. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

GEMLIEVA 200 MG Injection (Gemcitabine): A Fundamental Nucleoside Analog for Targeted Cancer Care GEMLIEVA 200 MG Injection is a sophisticated antineoplastic medication featuring the active pharmaceutical ingredient Gemcitabine. Classified as a pyrimidine nucleoside analog, it is a critical component in the systemic treatment of several aggressive solid tumors. Manufactured under stringent WHO-GMP guidelines, GEMLIEVA 200 MG is engineered to disrupt cancer cell DNA synthesis, making it a primary choice for oncologists managing advanced-stage malignancies globally. Therapeutic Indications and Clinical Usage Pancreatic Cancer: Indicated as a first-line treatment for patients with locally advanced or metastatic adenocarcinoma of the pancreas. Non-Small Cell Lung Cancer (NSCLC): Used in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced, or metastatic NSCLC. Breast Cancer: Employed in combination with paclitaxel for the treatment of patients with unresectable, localized, or metastatic breast cancer after the failure of prior anthracycline-based chemotherapy. Ovarian Cancer: Used in combination with carboplatin for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. Bladder Cancer: Frequently utilized in combination with cisplatin for advanced or metastatic transitional cell carcinoma of the urothelium. Mechanism of Action: How GEMLIEVA 200 MG Works Cellular Uptake: Once administered, Gemcitabine enters the cell and is converted into active metabolites (dFdCDP and dFdCTP). DNA Chain Termination: The active drug incorporates itself into the growing DNA strand during replication. Masked Termination: After Gemcitabine is added, only one additional nucleotide can be attached, which “masks“ the drug from the cell's repair enzymes. Inhibition of Ribonucleotide Reductase: It also blocks the enzyme responsible for creating the building blocks of DNA, effectively starving the cell of the resources it needs to grow. Apoptosis: This irreversible DNA damage triggers programmed cell death (apoptosis), leading to tumor shrinkage and halting the spread of metastasis. Professional Administration and Safety Protocols Route: Administered strictly via Intravenous (IV) Infusion. Infusion Timing: Typically administered over 30 minutes. Prolonging the infusion time beyond 60 minutes has been shown to increase toxicity. Dilution: Must be reconstituted with 0.9% Sodium Chloride Injection (without preservatives) to ensure stability. Clinical Oversight: Must be administered by qualified oncology professionals in a setting equipped for continuous patient monitoring. Safety Profile and Clinical Monitoring Hematological Vigilance: Regular Complete Blood Counts (CBC) are mandatory to monitor for bone marrow suppression (neutropenia, thrombocytopenia, and anemia). Hepatic and Renal Monitoring: Periodic liver and kidney function tests (LFTs/KFTs) are required to ensure the drug is being metabolized and excreted safely. Pulmonary Monitoring: Vigilance for rare but serious side effects like pulmonary toxicity or adult respiratory distress syndrome (ARDS). Flu-like Symptoms: Managing common side effects such as fever, headache, and chills, which often occur shortly after infusion. Storage and Global Handling Instructions Storage: Store the unreconstituted vial at controlled room temperature (20°C to 25°C). Reconstituted Solution: Once mixed, the solution should be used immediately or stored according to the manufacturer's stability guidelines to prevent microbial contamination. Cytotoxic Handling: As a hazardous antineoplastic agent, GEMLIEVA 200 MG must be prepared and handled using appropriate personal protective equipment (PPE) and disposed of according to international biohazard protocols. Why Choose Ernest Oncology? 100% Genuine Medication: We source directly from GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Logistics Precision: Our team manages pharmaceutical exports with expertise, utilizing secure packaging and efficient transit routes to maintain product stability during long-distance transit. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, clinics, and government health departments worldwide. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymediciensupplier.com | www.ernestimpex.com www.ernestvision.com | www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection